Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases

Hepatology

Volumn 49, Issue 1, 2009, Pages 250-257

  Brinker, Allen D ^a   Wassel, Ronald T ^a   Lyndly, Jenna ^a   Serrano, Jose ^b   Avigan, Mark ^a   Lee, William M ^c   Seeff, Leonard B ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; TELITHROMYCIN; ANTIINFECTIVE AGENT; KETOLIDE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRONCHITIS; CLINICAL ARTICLE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; JAUNDICE; LATENT PERIOD; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; NAUSEA; PLEURA EFFUSION; PRIORITY JOURNAL; SINUSITIS; TREATMENT INDICATION; WEAKNESS; CASE REPORT; CHEMICALLY INDUCED DISORDER; FATALITY; LIVER FAILURE; MIDDLE AGED; TOXIC HEPATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASCITES; FATAL OUTCOME; FEMALE; HEPATITIS, TOXIC; HUMANS; JAUNDICE; KETOLIDES; LIVER FAILURE; MALE; MIDDLE AGED; PLEURAL EFFUSION;

EID: 58949090373     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22620     Document Type: Article

References (44)

1. Brown SJ, Desmond PV. Hepatotoxicity of antimicrobial agents. Semin Liver Dis 2002;22:157-167.
2. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al for the Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129:512-521.
3. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. HEPATOLOGY 2005;42:481-489.
4. Wassel R, Brinker A. An evaluation of hepatic events associated with telithromycin (within Briefing Document, Division of Drug Risk Evaluation Office of Surveillance and Epidemiology, pages 23-50). Available at: Http://www.fda.gov/ohrms/dockets/ac/06/briefing/ 2006-4266b1-00-index.htm. Accessed June 11, 2008.
5. Sanofi-Aventis. Ketek (telithromycin) tablets. In: Physicians' Desk Reference. Montvale, NJ: Thomson PDR; 2005:710-717.
6. FDA Drug information on Ketek posted February 12, 2007. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01561.html. Accessed June 11, 2008.
7. Medical Officer Safety Review of NDA 21-144:TElithromycin (Ketek), March 31, 2004. http://www.fda.gov/cder/foi/nda/2004/21-144_Ketek.htm. Accessed July 11, 2008.
8. Alexander J. Pre-approval efficacy and safety data. Presentation before FDA Advisory Committee, Silver Spring, MD, December 12, 2006. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4266s1-00-index.htm. Accessed July 11, 2008.
9. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3rd, Banks PM. Brief communication: Severe hepatoToxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006;144:415-420.
10. Onur O, Guneysel O, Denizbasi A, Celikel C. Acute hepatitis attack after exposure to telithromycin. Clin Ther 2007;29:1725-1729.
11. Bolesta S, Roslund BP. Elevated hepatic transaminases associated with telithromycin therapy: A case report and literature review. Am J Health-Syst Pharm 2008;65:37-41.
12. Kessler DA. Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems. JAMA 1993;269: 2765-2768.
13. Brinker A, Beitz J. Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits. Clin Pharmacol Ther 2002; 71:99-102.
14. Hoofnagle JH. Drug-induced liver injury network (DILIN). HEPATOLOGY 2004;40:773.
15. Watkins PB, Seeff LB. Drug-induced liver injury: Summary of a single topic clinical research conference. HEPATOLOGY 2006;43:618-631.
16. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al., for the DILIN Study Group. Rationale, Design and Conduct of the Drug-Induced Liver Injury Network (DILIN) Prospective study. Drug Safety 2009;32(1).
17. Bjornsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006;79:521-528.
18. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998;20(Suppl C):C40-C44.
19. Sachs RM, Bortnichak EA. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986;81(Suppl 5B):49-55.
20. Bhasin S, Reyburn H, Steen J, Walker P. The effects of media publicity on spontaneous adverse reaction reporting with mefloquine in the UK. Pharmacoepidemiol Drug Safety 1997;6(Suppl 2):32.
21. Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: Analysis of spontaneously reported data. BMJ 1987;294:147-150.
22. Tsong Y. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting. J Biopharm Stat 1995;5:95-114.
23. Uetrecht J. Idiosyncratic drug reactions: Current understanding. Annu Rev Pharmacol Toxicol 2007;47:513-539.
24. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al., for the ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952.
25. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: A case study. Am J Med 2003;114:299-306.
26. Coleman CI, Spencer JV, Chung JO, Reddy P. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002;36:1162-1167.
27. Gholson CF, Warren GH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990;150:215-216.
28. Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, et al., for the Spanish Group for the Study of Drug-Induced Liver Disease. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. HEPATOLOGY 2006;44: 850-856.
29. Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER, eds. Diseases of the liver. 6th ed. Philadelphia: J.B. Lippincott, 1987:591-668.
30. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993;119:576-583.
31. Shaheen N, Grimm IS. Fulminant hepatic failure associated with clarithromycin. Am J Gastroenterol 1996;91:394-395.
32. Masiá M, Gutiérrez F, Jimeno A, Navarro A, Borrás J, Matarredona J, et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med 2002;162:474-476.
33. Christopher K, Hyatt PA, Horkan C, Yodice PC. Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol 2002;97:489-490.
34. Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krähenbühl S. Fulminant liver failure associated with clarithromycin. Anr. Pharmacother 2003;37:57-60.
35. Muller-Serieys C, Andrews J, Vacheron F, Cantalloube C. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 2004;53:149-157.
36. Pai MP, Momary KM, Rodvold KA. Antibiotic drug interactions. Med Clin North Am 2006;90:1223-1255.
37. Nguyen M, Chung EP. Telithromycin: The first ketolide antimicrobial. Clin Ther 2005;27:1144-1163.
38. Perrot X, Bernard N, Vial C, Antoine JC, Laurent H, Vial T, et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006;67:2256-2258.
39. Wassel R. Vision disorders, disturbances in consciousness, and exacerbations of myasthenia gravis. Presentation before FDA Advisory Committee, Silver Spring, MD, December 12, 2006. http://www.fda.gov/ ohrms/dockets/ac/06/slides/2006-4266s1-00-index.htm. Accessed June 11, 2008.
40. Bottenberg MM, Wall GC, Hicklin GA. Apparent anaphylactoid reaction after treatment with a single dose of telithromycin. Ann Allergy Asthma Immunol 2007;98:89-91.
41. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
42. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336.
43. Freston JW. Use and limitations of the RUCAM. AASLD-FDA-NIHPhRMA-Hepatotoxicity Steering Group Meeting, Bethesda MD, January 25-26, 2006. Slide presentation available at: Http://www.fda.gov/ CDER/livertox/presentations2006/Freston.pdf. Accessed August 22, 2008.
44. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, et al., for the Drug Induced Liver Injury Network. The reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. HEPATOLOGY 2008;48:1175-1183.